Hepatic stellate cell apoptosis (HSC apoptosis)

Hepatic stellate cell (HSC) apoptosis is a fundamental biological process essential for the regression and resolution of liver fibrosis (PMID: 11774063). In response to chronic liver injury, quiescent HSCs undergo activation into myofibroblast-like cells, which are the primary source of excessive extracellular matrix (ECM) deposition (StatPearls: Liver Fibrosis). The clearance of these activated cells through apoptosis is a prerequisite for the cessation of fibrogenesis and the subsequent remodeling of the liver parenchyma (PMID: 25600556). Therapeutic strategies aimed at inducing HSC apoptosis often target pro-apoptotic pathways such as the Bcl-2 family, death receptors like TRAIL, or the inhibition of survival signals like NF-κB (PMID: 15501411). However, a major challenge in drug development is ensuring that these pro-apoptotic signals are selectively delivered to activated HSCs to avoid collateral damage to healthy hepatocytes, which could lead to acute liver injury (PMID: 22433797). Successful induction of HSC apoptosis is often monitored by the reduction of activation markers like alpha-smooth muscle actin (α-SMA) and the presence of cleaved caspases within the stellate cell population.

Other names

HSC apoptosisProgrammed cell death of hepatic stellate cellsResolution of hepatic stellate cell activationStellate cell clearance

Induction of programmed cell death specifically in activated hepatic stellate cells to terminate the production of extracellular matrix and promote the regression of fibrotic tissue.